Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNJ013
MIFTS: 67

Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Conjunctivitis

About this section

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis 12 75 29 55 3 44 15 63 17 72 33
Madras Eye 12

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Eye diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:6195
ICD9CM 35 372.30
MeSH 44 D003231
NCIt 50 C34504
SNOMED-CT 68 9826008
UMLS 72 C0009763
Sources

Summaries for Conjunctivitis

About this section
PubMed Health : 63 About conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other. Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks. Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to giant papillary conjunctivitis and vernal conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pheniramine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

CDC : 3 People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Wikipedia : 75 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Conjunctivitis

About this section

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1412)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 34.2 RNASE3 IL4 CXCL8 CCL11
2 vernal conjunctivitis 33.7 RNASE3 IL4 IL2 IFNG
3 papillary conjunctivitis 33.7 IL6 IL4 CXCL8 CCL11
4 blepharoconjunctivitis 33.5 RNASE3 IL4 CCL11
5 chronic conjunctivitis 33.0 RNASE3 IL5 IL4 IL13 ICAM1 CCL11
6 rubella 32.2 TNF IL4 IL10
7 avian influenza 32.1 TNF IL6 CXCL8
8 reactive arthritis 31.9 TNF IL10 IFNG
9 kawasaki disease 31.9 TNF IL6 IL10
10 graves' disease 31.9 IL4 IFNG ICAM1
11 pollen allergy 31.8 RNASE3 IL5 IL13 ICAM1
12 stevens-johnson syndrome/toxic epidermal necrolysis 31.4 IL5 IL2 IL13 IFNG
13 hashimoto thyroiditis 31.3 IL4 IFNG ICAM1
14 measles 30.9 TLR3 IL6 IL4 IL2 IFNG
15 urticaria 30.5 RNASE3 NLRP3 HRH1
16 bullous pemphigoid 30.5 RNASE3 IL5 CCL11
17 cytokine deficiency 30.4 IL5 IL13
18 exanthem 30.4 TNF NLRP3 IL6 IL2
19 cardiogenic shock 30.3 TNF IL6
20 allergic conjunctivitis 30.3 TLR3 RNASE3 IL5 IL4 IL13 IFNG
21 cellulitis 30.1 TNF RNASE3 IL5
22 actinic prurigo 30.1 TNF IL13 ICAM1
23 erythema multiforme 30.0 TNF IL2 IFNG ICAM1
24 hypereosinophilic syndrome 30.0 RNASE3 IL5 IL4 IL13 CCL11
25 vulvovaginitis 29.9 IL10 CXCL8 CCL11
26 cystitis 29.9 TNF IL6 CXCL8
27 myelitis 29.9 TNF IL6 CCL11
28 mycobacterium abscessus 29.9 TNF NLRP3 CXCL8
29 dermatitis 29.8 IL5 IL4 IL13 IFNG CCL11
30 mumps 29.8 TNF IL2 IFNG
31 vernal keratoconjunctivitis 29.8 RNASE3 IL5 IL4 IL13 ICAM1 CCL11
32 gingivitis 29.8 TNF IL6 IL4 CXCL8
33 pyoderma gangrenosum 29.8 TNF NLRP3 CXCL8
34 keratoconjunctivitis sicca 29.8 TNF IL6 IL4 IL10
35 chlamydia 29.8 TNF IL6 IL4 IL10 IFNG CXCL8
36 neuritis 29.8 TNF IL4 IFNG
37 acute respiratory distress syndrome 29.8 TNF IL6 CXCL8
38 sarcoidosis 1 29.8 TNF IL2 IL13 IFNG
39 peanut allergy 29.7 IL13 IL10 IFNG
40 pertussis 29.7 TNF IL6 IL10
41 spinal cord injury 29.7 TNF IL6 CXCL8
42 necrotizing fasciitis 29.7 IL6 IL2 CXCL8
43 scabies 29.7 IL10 CXCL8 CCL11
44 sporotrichosis 29.7 IL10 IFNG
45 immune deficiency disease 29.7 IL4 IL2 IL13 IL10
46 lichen planus 29.7 TNF IL4 IFNG ICAM1
47 complex regional pain syndrome 29.7 TNF IL6 IL10
48 atherosclerosis susceptibility 29.6 TNF IL6 ICAM1
49 scleritis 29.6 TNF IL5 IL4 IFNG
50 sleep apnea 29.6 TNF IL6 ICAM1 CXCL8

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis
Sources

Symptoms & Phenotypes for Conjunctivitis

About this section

UMLS symptoms related to Conjunctivitis:


bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

GenomeRNAi Phenotypes related to Conjunctivitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CXCL8 ICAM1 IL10 IL2 NLRP3 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CXCL8 ICAM1 IL10 IL2 NLRP3 TNF

MGI Mouse Phenotypes related to Conjunctivitis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CCL11 HRH1 ICAM1 IFNG IL10 IL13
2 immune system MP:0005387 10.32 CCL11 HRH1 ICAM1 IFNG IL10 IL13
3 homeostasis/metabolism MP:0005376 10.31 HRH1 ICAM1 IFNG IL10 IL13 IL2
4 growth/size/body region MP:0005378 10.3 HRH1 ICAM1 IFNG IL10 IL13 IL2
5 digestive/alimentary MP:0005381 10.29 ICAM1 IFNG IL10 IL13 IL2 IL4
6 cellular MP:0005384 10.26 ICAM1 IFNG IL10 IL13 IL2 IL4
7 endocrine/exocrine gland MP:0005379 10.24 ICAM1 IFNG IL10 IL13 IL2 IL4
8 mortality/aging MP:0010768 10.18 HRH1 ICAM1 IFNG IL10 IL13 IL2
9 liver/biliary system MP:0005370 10.13 HRH1 IFNG IL10 IL2 IL4 IL5
10 integument MP:0010771 10.11 ICAM1 IFNG IL10 IL13 IL4 IL6
11 neoplasm MP:0002006 9.97 ICAM1 IFNG IL10 IL2 IL5 IL6
12 nervous system MP:0003631 9.96 ICAM1 IFNG IL10 IL13 IL4 IL6
13 muscle MP:0005369 9.91 ICAM1 IFNG IL10 IL13 IL6 TLR3
14 reproductive system MP:0005389 9.9 IFNG IL10 IL13 IL2 IL4 IL5
15 respiratory system MP:0005388 9.7 CCL11 IFNG IL10 IL13 IL2 IL4
16 vision/eye MP:0005391 9.23 ICAM1 IFNG IL10 IL2 IL4 IL6
Sources

Drugs & Therapeutics for Conjunctivitis

About this section

PubMed Health treatment related to Conjunctivitis: 63

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection, even though conjunctivitis is more commonly caused by viruses. But antibiotics are only effective against bacteria, and have no effect on viruses. If the infection is viral, only the symptoms can be treated. Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful. If conjunctivitis is caused by an allergy, it can be treated with allergy medicine such as antihistamines.

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
4
Alcaftadine Approved Phase 4 147084-10-4 19371515
5
Bepotastine Approved Phase 4 125602-71-3, 190786-44-8 2350
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Ofloxacin Approved Phase 4 82419-36-1 4583
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
13
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
14
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
20
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
21
Dipivefrin Approved Phase 4 52365-63-6 3105
22
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
Montelukast Approved Phase 4 158966-92-8 5281040
25
Ranibizumab Approved Phase 4 347396-82-1 459903
26
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
27
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
28
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
29
Tranilast Investigational Phase 4 53902-12-8 93543
30
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
31 Ketorolac Tromethamine Phase 4
32 Keratolytic Agents Phase 4
33 Dermatologic Agents Phase 4
34 Antipruritics Phase 4
35 Ophthalmic Solutions Phase 4
36 Anti-Infective Agents Phase 4
37 Anti-Bacterial Agents Phase 4
38 Topoisomerase Inhibitors Phase 4
39 Immunosuppressive Agents Phase 4
40 Calcineurin Inhibitors Phase 4
41 Hormone Antagonists Phase 4
42 Antiemetics Phase 4
43 Gastrointestinal Agents Phase 4
44 HIV Protease Inhibitors Phase 4
45 glucocorticoids Phase 4
46
protease inhibitors Phase 4
47 Antineoplastic Agents, Hormonal Phase 4
48 BB 1101 Phase 4
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
50 Antibiotics, Antitubercular Phase 4

Interventional clinical trials:

(show top 50) (show all 451)
# Name Status NCT ID Phase Drugs
1 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
2 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
3 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Unknown status NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
4 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaftâ„¢) Unknown status NCT01808768 Phase 4 Alcaftadine
5 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
6 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
7 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
8 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
9 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
10 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
11 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
12 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
13 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
14 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
15 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
16 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
17 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
18 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
19 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
20 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
21 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
22 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
23 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
24 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
25 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
26 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
27 A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis. Completed NCT00581542 Phase 4 moxifloxacin;polytrim
28 A Study to Evaluate the Efficacy of Lastacaft® Compared to Patadayâ„¢ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
29 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
30 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
31 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
32 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
33 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
34 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
35 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
36 Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings Completed NCT01433510 Phase 4 Grazax
37 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
38 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
39 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
40 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
41 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
42 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
43 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
44 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
45 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis Completed NCT01918956 Phase 4
46 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
47 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml
48 Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
49 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
50 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cromolyn
Cromolyn Sodium
Framycetin
Loteprednol
Neomycin
Ofloxacin
Oxymetazoline
Oxymetazoline hydrochloride
prednisolone
Prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Sulfacetamide
Tetracosactide

Cochrane evidence based reviews: conjunctivitis

Sources

Genetic Tests for Conjunctivitis

About this section

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 29
Sources

Anatomical Context for Conjunctivitis

About this section

MalaCards organs/tissues related to Conjunctivitis:

41
Eye, Testes, Skin, T Cells, Bone, Breast, Colon
Sources

Publications for Conjunctivitis

About this section

Articles related to Conjunctivitis:

(show top 50) (show all 10633)
# Title Authors PMID Year
1
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 9 38
20361659 2009
2
Traffic-related outdoor air pollution and respiratory symptoms in children: the impact of adjustment for exposure measurement error. 9 38
18379431 2008
3
IgE antibody on worn highly oxygen-permeable silicone hydrogel contact lenses from patients with contact lens-induced papillary conjunctivitis (CLPC). 9 38
18327049 2008
4
[Tumor necrosis factor receptor associated periodic syndrome (TRAPS). Report of two cases]. 9 38
17277873 2006
5
[Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis]. 9 38
16491868 2006
6
Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. 9 38
15245511 2004
7
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. 9 38
11443543 2001
8
Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. 9 38
11148813 2000
9
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 9 38
10756233 2000
10
Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. 9 38
9856836 1998
11
Eosinophil granule proteins expressed in ocular cicatricial pemphigoid. 9 38
9602632 1998
12
[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis]. 9 38
9759406 1998
13
Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. 9 38
8648032 1996
14
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. 9 38
8612470 1995
15
Impact of a school-based water, sanitation, and hygiene intervention on school absence, diarrhea, respiratory infection, and soil-transmitted helminths: results from the WASH HELPS cluster-randomized trial. 38
31360445 2019
16
α-Glucosidase inhibitory activity and in vivo antihyperglycemic effect of secondary metabolites from the leaf infusion of Ocimum campechianum mill. 38
31319121 2019
17
Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis. 38
31230264 2019
18
Osteoarticular manifestations of Mayaro virus infection. 38
31361271 2019
19
Pediatric Diffuse Large B-Cell Lymphoma of the Frontal Sinus: A Case Report. 38
30836788 2019
20
Effects of three husbandry systems on health, welfare and productivity of organic pigs. 38
30761969 2019
21
One-year evaluation of clinical and immunological efficacy and safety of sublingual versus subcutaneous allergen immunotherapy in allergic conjunctivitis. 38
31209565 2019
22
Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis. 38
31436181 2019
23
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. 38
31257177 2019
24
Colonization of therapeutic contact lens by dematiaceous fungi. 38
30981660 2019
25
The Prevalence of Bacteria, Fungi, Viruses, and Acanthamoeba From 3,004 Cases of Keratitis, Endophthalmitis, and Conjunctivitis. 38
31373904 2019
26
The change in the prevalence of wheeze, eczema and rhino-conjunctivitis among Japanese children: Findings from 3 nationwide cross-sectional surveys between 2005 and 2015. 38
30866051 2019
27
Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016. 38
31415382 2019
28
Chronic conjunctivitis as a prognosis factor of dacryocystorhinostomy: a retrospective case-controlled study. 38
31358137 2019
29
Clinical relevance of Zika symptoms in the context of a Zika Dengue epidemic. 38
31399372 2019
30
A Philophthalmid Eyefluke from a Human in Japan. 38
31418651 2019
31
Unbiased Pathogen Detection and Host Gene Profiling for Conjunctivitis. 38
30953744 2019
32
Use of Topical Steroids in Conjunctivitis: A Review of the Evidence. 38
31276464 2019
33
Mini-monoka stenting for patients with perennial allergic conjunctivitis. 38
30204032 2019
34
Omalizumab for atopic dermatitis: evidence for and against its use. 38
30717578 2019
35
Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. 38
30959559 2019
36
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? 38
31145194 2019
37
Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis. 38
31245879 2019
38
Cyclosporine 0.1% (Ikervis®) treatment in steroid-dependent dupilumab-associated conjunctivitis. 38
31178231 2019
39
Utility of the Pediatric Allergic Disease Quality of Life Questionnaire for childhood eczema. 38
30706447 2019
40
Allergic Diseases and Long Term Risk of Autoimmune Disorders: longitudinal cohort study and cluster analysis. 38
31413164 2019
41
Increased Risk of Atopic Diseases in the Siblings of Patients with Autism Spectrum Disorder: A Nationwide Population-Based Cohort Study. 38
31435817 2019
42
Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for the Treatment of Adenoviral Conjunctivitis. 38
31235065 2019
43
Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study. 38
31401340 2019
44
Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. 38
31372767 2019
45
Infective conjunctivitis progressing to posterior scleritis. 38
30912241 2019
46
Ocular Sporotrichosis: 26 Cases with Bulbar Involvement in a Hyperendemic Area of Zoonotic Transmission. 38
31411512 2019
47
Detection and identification of dust mite allergens in the air conditioning filters in Chandigarh, India. 38
31228070 2019
48
Evolving patterns of reactive arthritis. 38
30919146 2019
49
Comparative Effect of Feeding Human Milk as Opposed to Formula on Visual Function and Ocular Anatomy. 38
31368780 2019
50
Genetic features of Pseudomonas aeruginosa isolates associated with eye infections referred to Farabi Hospital, Tehran, Iran. 38
29982958 2019
Sources

Variations for Conjunctivitis

About this section
Sources

Expression for Conjunctivitis

About this section
Search GEO for disease gene expression data for Conjunctivitis.
Sources

Pathways for Conjunctivitis

About this section

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.1 TNF TLR3 RNASE3 NLRP3 MUC16 IL6
2
ERK Signaling 64
Show member pathways
 13.88 TNF IL6 IL5 IL4 IL2 IL13
3
PEDF Induced Signaling 64
Show member pathways
 13.74 TNF IL6 IL5 IL4 IL2 IL13
4
TGF-Beta Pathway 64
Show member pathways
 13.64 TNF IL6 IL5 IL4 IL2 IL13
5
Akt Signaling 64
Show member pathways
 13.51 TNF TLR3 IL6 IL5 IL4 IL2
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.47 TNF IL6 IL5 IL4 IL2 IL13
7
PAK Pathway 64
Show member pathways
 13.4 TNF IL6 IL5 IL4 IL2 IL13
8
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13.22 TNF TLR3 NLRP3 IL6 IL2 IL10
9
Pathways in cancer 37
12.95 IL6 IL5 IL4 IL2 IL13 IFNG
10
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 66
Show member pathways
 12.81 TNF TLR3 IL6 IFNG CXCL8
11
Th17 cell differentiation 37
Show member pathways
 12.74 TNF IL6 IL5 IL4 IL2 IL13
12
T cell receptor signaling pathway 37
Show member pathways
 12.72 TNF IL6 IL5 IL4 IL2 IL10
13
Immune response IL-23 signaling pathway 22
Show member pathways
 12.71 TNF PLG IL6 IL2 IL10 IFNG
14
Immune response NFAT in immune response 22
Show member pathways
 12.69 TNF IL4 IL2 IL10 IFNG
15
NF-kappaB Signaling 4
12.68 TNF TLR3 IL4 IL2 IL10 IFNG
16
Allograft rejection 37 1
Show member pathways
 12.67 TNF RNASE3 IL6 IL5 IL4 IL2
17
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.6 TNF IL4 IL2 IFNG ICAM1
18
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.56 IL6 IL5 IL4 IL2 IL13 IL10
19
Selenium Micronutrient Network 1
Show member pathways
 12.5 TNF PLG IL6 IL4 IL2 IFNG
20
IL-17 Family Signaling Pathways 65
Show member pathways
 12.48 TNF IL6 IL5 IL4 IL13 IFNG
21
Toll Comparative Pathway 64
Show member pathways
 12.41 TNF TLR3 IL6 IFNG CXCL8
22
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.4 TNF IL6 IL5 IL4 IL2 IL13
23
Human T-cell leukemia virus 1 infection 37
12.39 TNF IL6 IL2 ICAM1
24
Bacterial infections in CF airways 22
Show member pathways
 12.35 TNF IL6 IL4 IFNG CXCL8 CCL11
25
C-type lectin receptor signaling pathway 37
Show member pathways
 12.34 TNF NLRP3 IL6 IL2 IL10
26
Diseases associated with the TLR signaling cascade 66
Show member pathways
 12.32 TNF TLR3 IL6 CXCL8
27
Toxoplasmosis 37
Show member pathways
 12.32 TNF IL4 IL10 IFNG
28
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.31 TNF IL6 IL13 IL10 CXCL8
29
Tuberculosis 37
12.29 TNF IL6 IL10 IFNG
30
Necroptosis 37
Show member pathways
 12.28 TNF TLR3 NLRP3 IFNG
31
Colorectal Cancer Metastasis 64
12.25 TNF TLR3 IL6 IFNG
32
Th1 Differentiation Pathway 65
Show member pathways
 12.23 TNF TLR3 IL6 IL2 IL10 IFNG
33
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 12.21 TNF PLG IL6 IL4 IL13 IFNG
34
Spinal Cord Injury 1
12.2 TNF IL6 IL4 IL2 IFNG ICAM1
35
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.18 TNF IL6 IL5 IL4 IL2 IL10
36
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.17 IL6 IL5 IL4 IL2 IL13 IL10
37
MAPK Pathway 71
Show member pathways
 12.11 TLR3 IL5 IL2 IL13
38
Interleukin-4 and 13 signaling 66
12.09 TNF IL6 IL4 IL13 IL10 ICAM1
39
Amoebiasis 37
12.08 TNF IL6 IL10 IFNG CXCL8
40
Rheumatoid arthritis 37
12.04 TNF IL6 IFNG ICAM1 CXCL8
41
AGE-RAGE signaling pathway in diabetic complications 37
12.01 TNF IL6 ICAM1 CXCL8
42
Hematopoietic cell lineage 37
12 TNF IL6 IL5 IL4
43
TNF signaling pathway 37
11.98 TNF IL6 ICAM1
44
Jak-Stat Signaling Pathway (sino) 67
11.97 IL6 IL2 IL10 IFNG
45
Innate Lymphoid Cell Differentiation Pathways 65
11.97 TNF IL5 IL4 IL2 IL13 IL10
46
Senescence and Autophagy in Cancer 1
11.96 IL6 IFNG CXCL8
47
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.95 TNF IL5 IL4 IL2 IFNG CXCL8
48
NF-kappa B signaling pathway 37
11.94 TNF ICAM1 CXCL8
49
Pertussis 37
11.94 TNF NLRP3 IL6 IL10 CXCL8
50
Dendritic Cells Developmental Lineage Pathway 65
11.92 TNF IL6 IL2 IL10 IFNG
Sources

GO Terms for Conjunctivitis

About this section

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF RNASE3 PLG NLRP3 MUC16 IL6
2 extracellular space GO:0005615 9.5 TNF TLR3 RNASE3 PLG MUC16 IL6

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.99 TNF TLR3 RNASE3 IL10
2 positive regulation of gene expression GO:0010628 9.95 TNF TLR3 IL6 IL4 IL13 IFNG
3 defense response to virus GO:0051607 9.93 TLR3 NLRP3 IL6 IFNG
4 negative regulation of inflammatory response GO:0050728 9.89 NLRP3 IL2 IL10
5 defense response GO:0006952 9.89 TNF TLR3 NLRP3 CXCL8
6 cellular response to interferon-gamma GO:0071346 9.88 TLR3 ICAM1 CCL11
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 IL6 IL5 ICAM1
8 cellular response to interleukin-1 GO:0071347 9.87 ICAM1 CXCL8 CCL11
9 positive regulation of inflammatory response GO:0050729 9.87 TNF TLR3 IL2
10 response to glucocorticoid GO:0051384 9.85 TNF IL6 IL10
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 TNF IL6 IL5 IL10
12 immune response GO:0006955 9.85 TNF IL6 IL5 IL4 IL2 IL13
13 positive regulation of T cell proliferation GO:0042102 9.84 IL6 IL4 IL2
14 positive regulation of interleukin-6 production GO:0032755 9.84 TNF TLR3 IL6
15 response to virus GO:0009615 9.84 TNF TLR3 IFNG CCL11
16 humoral immune response GO:0006959 9.83 TNF IL6 IFNG
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 TNF IL6 IL13
18 defense response to Gram-positive bacterium GO:0050830 9.83 TNF RNASE3 NLRP3 IL6
19 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 TNF TLR3 NLRP3 IL6 ICAM1
20 extrinsic apoptotic signaling pathway GO:0097191 9.79 TNF TLR3 IFNG
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 TNF IFNG ICAM1
22 cellular response to lipopolysaccharide GO:0071222 9.73 TNF NLRP3 IL6 IL10 ICAM1 CXCL8
23 regulation of regulatory T cell differentiation GO:0045589 9.72 IL2 IFNG
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF IFNG
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 IL6 IL4 IL2 IL13 IFNG
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 TNF IL10
27 negative regulation of growth of symbiont in host GO:0044130 9.71 TNF IL10
28 positive regulation of B cell proliferation GO:0030890 9.71 IL5 IL4 IL2 IL13
29 response to molecule of bacterial origin GO:0002237 9.7 IL10 CXCL8
30 positive regulation of podosome assembly GO:0071803 9.7 TNF IL5
31 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
32 positive regulation of chemokine production GO:0032722 9.69 TNF TLR3 IL6
33 positive regulation of interleukin-13 production GO:0032736 9.68 NLRP3 IL4
34 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
35 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF TLR3
36 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL4 IL10
38 microglial cell activation GO:0001774 9.67 TNF TLR3 IL13
39 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 IL4 IL13 IL10 ICAM1
40 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.65 NLRP3 IL6
41 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF IL6
42 inflammatory response GO:0006954 9.65 TNF TLR3 NLRP3 IL6 IL5 IL13
43 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.64 TNF ICAM1
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.64 TNF IL10
45 necroptotic signaling pathway GO:0097527 9.63 TNF TLR3
46 positive regulation of immunoglobulin secretion GO:0051024 9.63 IL6 IL5 IL2
47 type 2 immune response GO:0042092 9.61 IL4 IL10
48 regulation of isotype switching GO:0045191 9.61 IL4 IL10
49 receptor biosynthetic process GO:0032800 9.58 TNF IL10
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IFNG

Molecular functions related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IL6 IL5 IL4 IL2 IL10
2 cytokine activity GO:0005125 9.32 TNF IL6 IL5 IL4 IL2 IL13
3 protein binding GO:0005515 10.03 TNF TLR3 PLG NLRP3 MUC16 IL6
Sources

Sources for Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....